Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
ERYTECH Pharma announces the strengthening of its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent.
ERYTECH réaffirme son éligibilité au PEA-PME pour 2015/2016
ERYTECH provides a business update and reports its financial results for the period ending December 31, 2014.
ERYTECH Pharma announces it has coopted Luc Dochez as new independent board member and will propose his appointment at the upcoming general assembly in June.
ERYTECH Pharma makes an oral presentation on April 30 Session 12 from 2:30 pm to 3:30 pm at CITIM 2015 congress which takes place from April 27 to 30 in Ljubljana, Slovenia.
ERYTECH Pharma is presenting 3 posters at ‘American Association for Cancer Research (AACR) Annual Meeting from April 18 to 22, 2015 in Philadelphie, PA, USA.
ERYTECH Pharma participates in BIOVISION on April 15 & 16, 2015 at Palais des Congrès in Lyon, France.
ERYTECH Pharma presents 2 posters at Société Française d’Hématologie Annual Congress which takes place in Paris, France from April 1st to 3rd, 2015.